BioSpace News Archive

Amphastar Pharmaceuticals, Inc. announced that the Company will release results for its second quarter of 2021 ended June 30, 2021, after the market closes on Monday, August 9th, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2021 financial results after the market closes on Thursday, August 5, 2021.

SCIEX, a global leader in life science analytical technologies, and Genedata, leading provider of biopharma enterprise software solutions, have entered into a strategic partnership to develop new software solutions for the biopharmaceutical mass spectrometry market.

Therma Bright Inc. currently trades on the OTC Pink Sheets under the symbol THRBF.

A team of neuroscientists and engineers at the Allen Institute, Princeton University and Baylor College of Medicine has just released a collection of data that marries a 3D wiring diagram with the function of tens of thousands of neurons to create the most detailed examination of mammalian brain circuitry to date.

Cartilage regeneration is a kind of regenerative medicine technology used to restore damaged articular joint cartilage.

The joint pain injection market is expected to reach US$ 6,996.88 million by 2028 from US$ 3,667.45 million in 2020; it is estimated to grow at a CAGR of 8.5% during 2021–2028.

AB Science SA (Euronext - FR0010557264 - AB) today announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimer’s disease have been presented at the annual Alzheimer’s Association International Conference (AAIC) (July 26-30, 2021).

Aethlon Medical, Inc., a medical device technology company focused on unmet needs in global health, announced that it will issue financial results for its first quarter fiscal year 2022, ended June 30, 2020, at 4:15 p.m. EST on Monday, August 9, 2021.

Keystone Bio, a biotechnology company, is a frontrunner in developing precision biologics to eliminate Porphyromonas gingivalis (Pg), and is releasing groundbreaking data that shows bacterial toxic proteins from Pg in the mouth are released into the blood and cross the Blood Brain Barrier (BBB) as the major driver of sporadic Alzheimer’s and chronic inflammation.